Susquehanna International Group
CRDF icon

Susquehanna International Group’s Cardiff Oncology CRDF Stock Holding History

Susquehanna International Group’s Portfolio CRDF Stock Details CRDF Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$439K Buy
270,900
+75,100
+38% +$154K ﹤0.01% 9993
2025
Q4 		$550K Buy
195,800
+11,700
+6% +$27.2K ﹤0.01% 8550
2025
Q3 		$379K Buy
184,100
+150,900
+455% +$417K ﹤0.01% 9590
2025
Q2 		$105K Buy
+33,200
New +$101K ﹤0.01% 11775
2025
Q1 		– Sell
-41,000
Closed -$178K – 12597
2024
Q4 		$178K Sell
41,000
-117,800
-74% -$368K ﹤0.01% 10855
2024
Q3 		$424K Buy
158,800
+28,200
+22% +$66.6K ﹤0.01% 8868
2024
Q2 		$290K Buy
130,600
+31,000
+31% +$117K ﹤0.01% 9520
2024
Q1 		$532K Buy
99,600
+88,700
+814% +$236K ﹤0.01% 8353
2023
Q4 		$16.1K Sell
10,900
-151,300
-93% -$183K ﹤0.01% 12009
2023
Q3 		$225K Buy
+162,200
New +$274K ﹤0.01% 9971
2021
Q4 		– Sell
-37,500
Closed -$250K – 13190
2021
Q3 		$250K Sell
37,500
-5,600
-13% -$35.2K ﹤0.01% 11009
2021
Q2 		$287K Buy
43,100
+9,500
+28% +$80.6K ﹤0.01% 10851
2021
Q1 		$311K Sell
33,600
-174,800
-84% -$2.12M ﹤0.01% 10515
2020
Q4 		$3.75M Sell
208,400
-54,200
-21% -$953K ﹤0.01% 3928
2020
Q3 		$3.73M Buy
+262,600
New +$1.73M ﹤0.01% 3508
2016
Q3 		– Sell
-3,872
Closed -$1.26M – 8459
2016
Q2 		$1.26M Buy
3,872
+1,834
+90% +$632K ﹤0.01% 4385
2016
Q1 		$682K Buy
2,038
+894
+78% +$304K ﹤0.01% 5843
2015
Q4 		$445K Sell
1,144
-63
-5% -$24.7K ﹤0.01% 6995
2015
Q3 		$494K Buy
1,207
+1,042
+632% +$545K ﹤0.01% 7147
2015
Q2 		$121K Sell
165
-41
-20% -$29.1K ﹤0.01% 9599
2015
Q1 		$101K Sell
206
-40
-16% -$17.1K ﹤0.01% 8959
2014
Q4 		$76K Buy
+246
New +$79.6K ﹤0.01% 9269

Other funds holding CRDF

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
FLPIM
F.L. Putnam Investment Management Lynnfield, Massachusetts $6.71B AUM 23.99% 1-Year Est. Return

Susquehanna International Group's CRDF Position: Q1 2026 in Review

Susquehanna International Group increased its Cardiff Oncology (CRDF) stake by 323% in Q1 2026, buying an estimated $145K and bringing the position to 92,359 shares worth $150K. The position accounts for ﹤0.01% of the portfolio, ranked #12004.

Susquehanna International Group first reported a position in CRDF in Q1 2015 and has held it in 35 quarters since. The position peaked at $4.46M in Q4 2020. 116 funds tracked by Wall St. Rank hold CRDF as of Q1 2026.

  • Susquehanna International Group held 92,359 shares of Cardiff Oncology worth $150K as of Q1 2026.
  • Susquehanna International Group bought 70,519 Cardiff Oncology shares in Q1 2026, an estimated $145K.
  • Cardiff Oncology made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #12004 holding.
  • Susquehanna International Group first reported a position in Cardiff Oncology in Q1 2015 and has held it in 35 quarters since.
  • Susquehanna International Group's Cardiff Oncology position peaked at $4.46M in Q4 2020.
  • 116 funds tracked by Wall St. Rank held Cardiff Oncology as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.